Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:COGT NASDAQ:ITOS NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.67+2.4%$4.66$1.89▼$6.51$1.69B0.695.11 million shs2.57 million shsCOGTCogent Biosciences$16.78+3.2%$12.84$3.72▼$16.99$1.91B0.31.94 million shs614,069 shsITOSiTeos Therapeutics$10.15$10.14$4.80▼$17.63$448.73M1.311.51 million shsN/ATLRYTilray Brands$1.69-2.0%$1.24$0.35▼$2.32$1.87B1.9848.87 million shs37.07 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%-6.27%+23.71%+30.42%+113.51%COGTCogent Biosciences0.00%+3.24%+28.52%+46.71%+44.62%ITOSiTeos Therapeutics0.00%0.00%0.00%-1.93%+2.01%TLRYTilray Brands0.00%+6.17%+53.57%+161.88%+5.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.67+2.4%$4.66$1.89▼$6.51$1.69B0.695.11 million shs2.57 million shsCOGTCogent Biosciences$16.78+3.2%$12.84$3.72▼$16.99$1.91B0.31.94 million shs614,069 shsITOSiTeos Therapeutics$10.15$10.14$4.80▼$17.63$448.73M1.311.51 million shsN/ATLRYTilray Brands$1.69-2.0%$1.24$0.35▼$2.32$1.87B1.9848.87 million shs37.07 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%-6.27%+23.71%+30.42%+113.51%COGTCogent Biosciences0.00%+3.24%+28.52%+46.71%+44.62%ITOSiTeos Therapeutics0.00%0.00%0.00%-1.93%+2.01%TLRYTilray Brands0.00%+6.17%+53.57%+161.88%+5.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.71Moderate Buy$8.0041.22% UpsideCOGTCogent Biosciences 2.77Moderate Buy$20.0019.16% UpsideITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsideTLRYTilray Brands 2.00Hold$2.0018.69% UpsideCurrent Analyst Ratings BreakdownLatest ITOS, COGT, TLRY, and ABCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/9/2025TLRYTilray BrandsAtb Cap MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/8/2025ABCLAbCellera BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025COGTCogent BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TLRYTilray BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ABCLAbCellera BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025COGTCogent BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TLRYTilray BrandsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/2/2025COGTCogent BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$30.008/25/2025COGTCogent BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$17.00 ➝ $20.008/25/2025TLRYTilray BrandsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.50 ➝ $2.008/8/2025ABCLAbCellera BiologicsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.00(Data available from 10/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$32.88M51.49N/AN/A$3.58 per share1.58COGTCogent BiosciencesN/AN/AN/AN/A$1.32 per shareN/AITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91TLRYTilray Brands$210.48M8.81$0.14 per share11.90$1.40 per share1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.55N/AN/AN/A-511.88%-16.17%-12.24%11/6/2025 (Confirmed)COGTCogent Biosciences-$255.86M-$1.78N/AN/AN/AN/A-223.82%-89.44%11/11/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)TLRYTilray Brands-$2.19B-$2.27N/AN/AN/A-258.54%-6.79%-5.30%N/ALatest ITOS, COGT, TLRY, and ABCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ABCLAbCellera Biologics-$0.17N/AN/AN/A$6.33 millionN/A10/9/2025Q1 2026TLRYTilray Brands-$0.03-$0.0002+$0.0298N/A$205.75 million$209.50 million8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17-$0.12+$0.05-$0.12$7.55 million$17.08 million8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A8/5/2025Q2 2025COGTCogent Biosciences-$0.55-$0.53+$0.02-$0.53N/AN/A7/28/2025Q4 2025TLRYTilray Brands-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A11.0711.07COGTCogent BiosciencesN/A4.194.19ITOSiTeos TherapeuticsN/A7.537.53TLRYTilray Brands0.152.621.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%COGTCogent BiosciencesN/AITOSiTeos Therapeutics97.16%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%COGTCogent Biosciences7.29%ITOSiTeos Therapeutics14.20%TLRYTilray Brands0.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.83 million212.47 millionOptionableCOGTCogent Biosciences80113.86 million105.56 millionOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionableTLRYTilray Brands2,8421.10 billion1.09 billionOptionableITOS, COGT, TLRY, and ABCL HeadlinesRecent News About These CompaniesTilray Brands, Inc. (NASDAQ:TLRY) Q1 2026 Earnings Call Transcript4 hours ago | msn.comCannabis Stocks To Follow Now - October 12thOctober 12 at 1:02 PM | marketbeat.comTilray Brands, Inc. (NASDAQ:TLRY) Receives Average Rating of "Hold" from AnalystsOctober 12 at 4:15 AM | marketbeat.comCannabis Stocks To Consider - October 11thOctober 11 at 1:00 PM | marketbeat.comTop 3 Canadian Cannabis Stocks to Watch in October 2025October 11 at 10:00 AM | marijuanastocks.comMTilray Brands (NASDAQ:TLRY) Stock Rating Lowered by Atb Cap MarketsOctober 11 at 6:23 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Upgraded by Wall Street Zen to "Hold" RatingOctober 11 at 2:57 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 18.1% - Time to Sell?October 10 at 5:40 PM | marketbeat.comPromising Cannabis Stocks To Follow Now - October 10thOctober 10 at 1:12 PM | marketbeat.comWhy Tilray Brands Stock Just Stubbed OutOctober 10 at 1:01 PM | fool.comDelta, Pepsi, Applied Digital, Levi's, Tilray Brands kick off Q3 earnings seasonOctober 10 at 11:32 AM | proactiveinvestors.comTilray Brands (NASDAQ:TLRY) Shares Gap Down - Here's WhyOctober 10 at 11:21 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Up 22.1% - Here's WhyOctober 9, 2025 | marketbeat.comTilray Brands Reports Record Revenue and ProfitabilityOctober 9, 2025 | tipranks.comTilray Brands (TLRY) Hits All-Time High on Stellar Q1 EarningsOctober 9, 2025 | insidermonkey.comLive: Tilray Brands (TLRY) Q1 FY2026 Earnings CoverageOctober 9, 2025 | 247wallst.comTilray Brands (NASDAQ:TLRY) Hits New 52-Week High - Time to Buy?October 9, 2025 | marketbeat.comTilray stock: why options data is skewed to downside despite solid Q1 earningsOctober 9, 2025 | invezz.comITilray Brands, Inc. (TLRY) Q1 2026 Earnings Call TranscriptOctober 9, 2025 | seekingalpha.comTilray: Another Blah QuarterOctober 9, 2025 | seekingalpha.comCannabis Stocks To Watch Today - October 9thOctober 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Is Tilray's Stock Price Surge a Pipe Dream of Political Hype?By Jeffrey Neal Johnson | October 1, 2025ITOS, COGT, TLRY, and ABCL Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.66 +0.14 (+2.44%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Cogent Biosciences NASDAQ:COGT$16.78 +0.51 (+3.16%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.iTeos Therapeutics NASDAQ:ITOSiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Tilray Brands NASDAQ:TLRY$1.68 -0.04 (-2.03%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
